Growth momentum Collegium Pharmaceutical is a rising specialty pharma player with a diversified portfolio and substantial revenue trajectory, presenting ongoing opportunities to expand relationships across high-value healthcare providers, payers, and distribution channels.

Strategic acquisition The recent acquisition of Azstarys from Corium Therapeutics indicates a strategy to bolster ADHD franchise assets and pipeline depth, suggesting sales opportunities to broaden formulary access and cross-sell complementary neurological and psychiatric therapies.

Geographic expansion Relocation to Boston’s Financial District signals an emphasis on attracting top talent and potentially expanding commercial and clinical outreach capabilities in a major biotech hub, enabling deeper engagement with hospital systems, researchers, and regional payers.

Financial health Strong quarterly performance with solid revenue and EBITDA metrics, plus a robust funding base, supports more aggressive market access strategies, co-promotion opportunities, and expanded clinical support for specialty products.

Intellectual property risk Ongoing patent litigation activity around key Orange Book assets creates a need for proactive market access and competitive positioning discussions with stakeholders focused on long-term product viability and lifecycle management.